Iovance Biotherapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell IOVA and other ETFs, options, and stocks.

About IOVA

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. 

CEO
Frederick G. Vogt
CEOFrederick G. Vogt
Employees
975
Employees975
Headquarters
San Carlos, California
HeadquartersSan Carlos, California
Founded
2007
Founded2007
Employees
975
Employees975

IOVA Key Statistics

Market cap
1.60B
Market cap1.60B
Price-Earnings ratio
-3.38
Price-Earnings ratio-3.38
Dividend yield
Dividend yield
Average volume
19.41M
Average volume19.41M
High today
$3.91
High today$3.91
Low today
$3.65
Low today$3.65
Open price
$3.78
Open price$3.78
Volume
15.12M
Volume15.12M
52 Week high
$5.64
52 Week high$5.64
52 Week low
$1.64
52 Week low$1.64

Stock Snapshot

As of today, Iovance Biotherapeutics(IOVA) shares are valued at $3.89. The company's market cap stands at 1.6B, with a P/E ratio of -3.38.

During the trading session on 2026-02-27, Iovance Biotherapeutics(IOVA) shares reached a daily high of $3.91 and a low of $3.65. At a current price of $3.89, the stock is +6.4% higher than the low and still -0.5% under the high.

Trading activity shows a volume of 15.12M, compared to an average daily volume of 19.41M.

The stock's 52-week range extends from a low of $1.64 to a high of $5.64.

The stock's 52-week range extends from a low of $1.64 to a high of $5.64.

IOVA News

Nasdaq 3d
Stock Market Today, Feb. 24: Broad Rally Lifts Markets As Investors Look Ahead to Nvidia Earnings Tomorrow and Trump's State of the Union

The S&P 500 (SNPINDEX:^GSPC) rose 0.78% to 6,891.04, the Nasdaq Composite (NASDAQINDEX:^IXIC) gained 1.04% to 22,863.68, and the Dow Jones Industrial Average (D...

Stock Market Today, Feb. 24: Broad Rally Lifts Markets As Investors Look Ahead to Nvidia Earnings Tomorrow and Trump's State of the Union
Benzinga 3d
Iovance Biotherapeutics Explodes Over 20% — Early Trial Data Sparks Investor Frenzy

Iovance Biotherapeutics (NASDAQ:IOVA) shares are surging on Tuesday following the announcement of positive early data from a pilot clinical trial for its TIL ce...

Iovance Biotherapeutics Explodes Over 20% — Early Trial Data Sparks Investor Frenzy
TipRanks 3d
Iovance Highlights Amtagvi Revenue Growth and Profitability Path

Iovance Biotherapeutics ( (IOVA) ) has provided an update. On February 24, 2026, Iovance Biotherapeutics reported that 2025 was its first full calendar year of...

Analyst ratings

80%

of 10 ratings
Buy
80%
Hold
20%
Sell
0%

More IOVA News

TipRanks 3d
Iovance Biotherapeutics reports Q4 EPS (18c), consensus (18c)

Reports Q4 revenue $86.711M, consensus $81.01M. Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer of Iovance, stated, “Iovance delivere...

TipRanks 3d
Iovance Biotherapeutics announces results from trial for TIL cell therapy

Iovance Biotherapeutics (IOVA) announced positive early data from a pilot clinical trial led by Memorial Sloan Kettering Cancer Center, MSKCC, and supported by...

People also own

Based on the portfolios of people who own IOVA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.